Economic evaluation aims to inform decision making about new medical technologies but its impact on uptake is unclear. The UK's Medical Technologies Evaluation Programme (MTEP) evaluates devices but uptake is not mandatory and guidance may be outdated by long timelines. Efforts like the Health Technologies Adoption Program help uptake but lack metrics. For economic evaluation to increase uptake in Ireland, appropriate timelines and fit-for-purpose methodologies are needed, and a link between guidance and mandatory uptake should be established.
Ignite your medical funding opportunties emeAlan Scrase
IGNITE your.... medical funding opportunities
Presenter - Dr Lisa Douet, Senior Research Fellow, and Ellie Monks, EME Programme Manager will present about
“Research Funding: The Efficacy and Mechanism Evaluation Programme”
The EME Programme funds clinical efficacy studies. The studies it supports usually test if an intervention works as expected, in a well-defined population or group of patients. The Programmealso also provides an opportunity to use clinical studies to understand disease or treatment mechanisms, which may in turn lead to improvements in health and patient care.
Ignite your medical funding opportunties emeAlan Scrase
IGNITE your.... medical funding opportunities
Presenter - Dr Lisa Douet, Senior Research Fellow, and Ellie Monks, EME Programme Manager will present about
“Research Funding: The Efficacy and Mechanism Evaluation Programme”
The EME Programme funds clinical efficacy studies. The studies it supports usually test if an intervention works as expected, in a well-defined population or group of patients. The Programmealso also provides an opportunity to use clinical studies to understand disease or treatment mechanisms, which may in turn lead to improvements in health and patient care.
ECO 11: Transfer of Care to Pharmacy - Hassan Argomandkhah, Chair of Pharmacy...Innovation Agency
Hassan introduces the concept and key objectives of transfer of care to pharmacy (TCP). The slides include a project outline, an overview of TCP in Cheshire and Merseyside, and the benefits and potential savings of Electronic Transfer of Care to Pharmacy.
‘In with the old, out with the new’ – In search of ways to help health economists break their addiction to technology adoption. CHE Seminar presented by Professor Stirling Bryan, Director, Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute, Professor, School of Population & Public Health, University of British Columbia. 17th October 2014
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
Health technology assessment (HTA) is familiar as technique for gauging the value of specific medical technologies or approaches to care. As Adrian Towse points out, however, HTA has a much broader, ‘macro’ role in contributing to the efficiency of health care systems and supporting universal health coverage. This is particularly crucial in the face of increasing demands and limited budgets.
Novo Nordisk introducing the Coalition for Sustainable Pharmaceuticals and Me...UN SPHS
Anne Gadegaard, Global Senior Advisor of Novo Nordisk has delivered a presentation on 11 May 2016 at the dialogue on “Fostering Sustainable Procurement: How Procurers Can Change the Global Health Sector” in UN City, Copenhagen.
Co-ordinated malaria research for better policy and practice: the role of res...ACT Consortium
Prof. David Schellenberg from the London School of Hygiene & Tropical Medicine presents on behalf of the ACT Consortium at the European Congress on Tropical Medicine and International Health in Basel, Switzerland, 8 September 2015
Health Technology Assessment (HTA) Report: Interventions to increase particip...HTAi Bilbao 2012
Health Technology Assessment (HTA) Report: Interventions to increase participation to organised cancer screening programs
Ministry of Health Grant for Applied Research
Giorgi Rossi P, Camilloni L, Ferroni E, Jimenez B, Furnari G, Guasticchi G, Borgia P.
Laziosanità – Agenzia di Sanità Pubblica della Regione Lazio
ECO 11: Transfer of Care to Pharmacy - Hassan Argomandkhah, Chair of Pharmacy...Innovation Agency
Hassan introduces the concept and key objectives of transfer of care to pharmacy (TCP). The slides include a project outline, an overview of TCP in Cheshire and Merseyside, and the benefits and potential savings of Electronic Transfer of Care to Pharmacy.
‘In with the old, out with the new’ – In search of ways to help health economists break their addiction to technology adoption. CHE Seminar presented by Professor Stirling Bryan, Director, Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute, Professor, School of Population & Public Health, University of British Columbia. 17th October 2014
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
Health technology assessment (HTA) is familiar as technique for gauging the value of specific medical technologies or approaches to care. As Adrian Towse points out, however, HTA has a much broader, ‘macro’ role in contributing to the efficiency of health care systems and supporting universal health coverage. This is particularly crucial in the face of increasing demands and limited budgets.
Novo Nordisk introducing the Coalition for Sustainable Pharmaceuticals and Me...UN SPHS
Anne Gadegaard, Global Senior Advisor of Novo Nordisk has delivered a presentation on 11 May 2016 at the dialogue on “Fostering Sustainable Procurement: How Procurers Can Change the Global Health Sector” in UN City, Copenhagen.
Co-ordinated malaria research for better policy and practice: the role of res...ACT Consortium
Prof. David Schellenberg from the London School of Hygiene & Tropical Medicine presents on behalf of the ACT Consortium at the European Congress on Tropical Medicine and International Health in Basel, Switzerland, 8 September 2015
Health Technology Assessment (HTA) Report: Interventions to increase particip...HTAi Bilbao 2012
Health Technology Assessment (HTA) Report: Interventions to increase participation to organised cancer screening programs
Ministry of Health Grant for Applied Research
Giorgi Rossi P, Camilloni L, Ferroni E, Jimenez B, Furnari G, Guasticchi G, Borgia P.
Laziosanità – Agenzia di Sanità Pubblica della Regione Lazio
Stuart Lane on prognostication post out of hospital cardiac arrestSMACC Conference
Always controversial, always entertaining, the fearsome but loveable Geordie Stuart Lane gives an excellent summary of a core ICU topic: managing out of hospital cardiac arrests. Nearly at the end of the BCC3 series - and in only a month we're doing it all again, this time in tropical Cairns - come and join us.
In the presentation efforts have been made to guide the medical professionals how to deal with a MLC case in a step by step manner and certain issues relating to medical case records.
Seeking value: Experience from the UK's National Institute for Health and Car...OECD Governance
This presentation was made by Tommy Wilkinson, United-Kingdom, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems, held in Paris on 16-17 February 2015.
Presentation by David Wonderling, Head of Health Economics at National Guideline Centre, Royal College of Physicians and Lauren Ramjee, Senior Health Economist, Royal College of Physicians.
This workshop outlines the principles of health economic evaluation for the NHS.
Presentation - The Economics of the Market for Medicines, Jorge Mestre-Ferran...Office of Health Economics
Jorge Mestre-Ferrandiz also presented a guest lecture at City University, London, on 17 March 2016, on the topic of the economics of the market for medicines.
The first half of the lecture included an overview of the global challenges facing medicines manufacturers, discussion of the ‘supply side’ (focusing on research and development of new drugs), and evidence relating to the ‘demand side’ which suggests that UK spending on medicines as a percentage of GDP is already amongst the lowest in developed countries.
The second half of the lecture looked at NICE and the ‘hurdle’ of demonstrating cost-effectiveness, as well as an overview of pricing regulation, and specific characteristics of the UK market.
An introduction on Evidence-Based Clinical Practice Guidelines in Health Care Organizations
Brief on Alexandria Center for EBCPGs in Alexandria University Hospitals, Egypt
By Dr. Yasser Sami Abdel Dayem Amer, MBBCh, MS 2013
Special Thanks to
Prof Dr Mahmoud Elzalabany
Prof Dr Tarek Omar
Prof Dr Nabil Dowidar
Prof Dr Afaf Gaber
The MaRS EXCITE (Excellence in Clinical Innovation and Technology Evaluation) program helps innovators collaborate with the health system to accelerate the pace of adoption of innovative health technologies in Ontario and global markets.
At the end of the program, innovators will have feedback and data on the effectiveness, competitiveness, and economic value of their medical devices or health technology. With this data, innovators are better equipped to approach payers in multiple markets for reimbursement.
Prioritized by senior executives from the health system, only technologies that have true breakthrough potential are allowed into the program.
For more information visit www.marsdd.com.
OHE’s Professor Nancy Devlin has researched, written and spoken widely on the use of the EQ-5D, and related measures, both in her capacity as the Director of Research at the OHE and as Chair of the Executive Committee of the EuroQol Group.
In May, Nancy was invited to participate in the “Workshop on measuring patient-reported outcomes using the EQ-5D”, which was organised by the Swedish National Board of Health and Welfare in collaboration with the EuroQol Group. The workshop brought together policy makers and researchers in Sweden interested in measuring patients’ health outcomes.
Sweden has included the EQ-5D in some of its quality registries and in population health surveys for many years. The Swedish National Board of Health and Welfare now is exploring whether and how to extend use of patient reported outcomes measures in the health care system, including the EQ-5D, to both monitor the quality of providers and services and to facilitate health technology appraisal.
Nancy’s talk, shown below, introduced the EQ-5D instrument; discussed how data from it can be analysed; identified some of the challenges in analysis; and commented on the future of outcomes measurement.
Placing the Evolution of HTA In Emerging Markets in Context of Health System ...Office of Health Economics
These slides were presented by Professor Adrian Towse at the 9th World Congress of the International Health Economics Association in July 2013. The presentation examined how the development of health care systems affect the evolution of the use of health technology assessment. Three countries provide case studies: Brazil, China and Taiwan.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.
1. Does Economic Evaluation lead to
increased uptake of new medical
technologies?
Brenda Dooley
March 25th 2015
2. For consideration today
• What is Economic Evaluation?
• Methodological approaches in current use?
• Impact of evaluation decisions made in one jurisdiction
• Relevance for Ireland
3. What is an Economic Evaluation?
• Formal assessment of the major health effects a
new technology will have on the patient and the
health care system.
• Purpose is to inform decision making & meet the
needs of the decision maker.
• Assessment methods and practices need to fit
the technologies to be assessed, specific to the
decision to inform.
• Positive outcome should lead to funding and
uptake of new technology.
4. Differences between health innovations?
• Process of innovation for medical
devices and pharmaceuticals
differs greatly
• Dissimilar mechanism of action
• Product lifecycle
• Provision of robust clinical
evidence – v challenging for
medical devices
• Ready established pathways for
evaluation of pharmaceuticals not
entirely suitable for medical
technologies.
6. Medical Technologies Evaluation Programme (MTEP)
• MTEP provides a single entry point for manufacturers to submit
products for evaluation – then routed to appropriate evaluation
programme
• Overall objectives threefold – to simplify access to, speed up and
increase evaluation capacity for medical devices
• Products must have a CE mark, be new or represent a significant
modification and have clear benefits for patients of NHS
• 1st MTEP guidance published in 2010
• Recommended technologies not subject to mandatory funding
7. Methodological Approach by MTEP
• Cost Consequence Analysis – no attempt to summarise the benefits into
a single outcome measure.
• Subjective decision making - relative value of each outcome
considered.
• Limitations of the CCA - a medical device is only more beneficial than
current practice if it is resource releasing.
• Approach to evidence synthesis.
• “it (NICE) may discriminate against technologies that would ultimately
provide a net benefit to the NHS” 1
1. Greene W and Hutton J . Health technology assessments in England: an analysis of
the NICE Medical Technologies Evaluation Programme. Eur J Health Econ. 2014 .
8. Has MTEP been successful to date ?
• Medical Technology Guidance ( MTG ) published for 15 technologies in
initial 3 years of MTEP.
• Target for year 1 = 15 50 in future years
• 4 MTG published in 1st year
Overall
Evaluations
( 2010-2013 )
Recommended ,
some with
specific
circumstances
Further
research
required
Not
Recommended
15 12 2 1
9. Has MTEP been successful ?
2. Chapman, A.M., Taylor, C.A., & Girling, A.J., 2014. Are the UK Systems of Innovation and
Evaluation of Medical Devices Compatible? The Role of NICE's Medical Technologies Evaluation
Programme (MTEP). Appl Health Econ Health Policy, 12(4), pp.347-357.
10. Has MTEP been successful to date ?
2.Chapman, A.M., Taylor, C.A., & Girling, A.J., 2014. Are the UK Systems of Innovation and
Evaluation of Medical Devices Compatible? The Role of NICE's Medical Technologies
Evaluation Programme (MTEP). Appl Health Econ Health Policy, 12(4), pp.347-357.
By mid 2014,
nearly 2/3
exceeded
target with avg
of 16.7 mo’s 2
11. Has MTEP been successful to date ?
• While MTEP provides an accessible entry point for companies wishing to
submit a product for evaluation, barriers exist
• The current process at NICE attracts a small subset of mainly large
device manufacturers.
• Due to current evaluation timelines, high risk of guidance being
outdated prior to uptake.
• No Mandatory uptake of MTEP guidance in England.
12. NICE efforts to support uptake of new technologies
• Health Technologies Adoption Program (HTAP)
• Develops resources to aid the adoption of NICE guidance
• Topics selected are those identified as having potential adoption
barriers in England
• HTAP teams works with the NHS with a) demonstrator projects or
b) adoption projects
13. An Example
• Ambu aScope2 system; sterile, single-
patient use endoscope and reusable
monitor for complex intubations.
• During development of NICE guidance -
Ambu aScope3 launched
• HTAP developed a site demonstrator
pack to aid implementation & uptake
of usage : including info on new design
• One major limitation : no metrics on
impact of HTAP
Copyright Ambu Ltd
2013
Copyright Ambu Ltd 2013
14. Relevance for Ireland
• AdvaMed report recommends “use of value based criteria should be
routine in medical device procurement vs simplistic recourse to
procurement based on lowest price” 3
• IMSTA has called for a multi disciplinary Professional Evaluation Group
to be established to standardise medical technology Evaluation in
Ireland
• Also conducting a piece of work examining the issues associated with
how clinical investigations are currently conducted here
• Objective is a list of recommendations to help standardise how
evidence is collected in clinical investigations
3. IMSTA publication “New Approaches for procuring effective healthcare solutions”
published with permission of AdvaMed 2014
15. Conclusions
• The MTEP experience would suggest that evaluation of medical
technologies to date has not led to increased uptake
• Partly due to design of the MTEP
• Recent developments indicate willingness to address gaps in uptake
• Key learnings for Ireland if economic evaluation is to be introduced
• Appropriate timelines central coupled with appropriate methodologies
that are fit for purpose of evaluating medical technologies
• NB. A link should be established between guidance and uptake